Acer Therapeutics Inc. (ACER) |
|
0.75 -0.022 (-2.85%)
|
03-24 16:00 |
|
Open: |
0.7701 |
Pre. Close: |
0.772 |
|
High:
|
0.8 |
Low:
|
0.743 |
|
Volume:
|
121,293 |
Market Cap:
|
17(M) |
|
|
|
Technical analysis |
as of: 2023-03-24 4:23:44 PM |
|
Overall:
|
  |
| Stoxline posted a NEUTRAL today, upgraded from lower rating. Current trend continues, but could change at anytime. It is not a good time to buy or sell. |
| Target: |
Six months: 1.98 One year: 2.74 |
| Support: |
Support1: 0.65 Support2: 0.54 |
| Resistance: |
Resistance1: 1.7 Resistance2: 2.34 |
| Pivot: |
1.32  |
| Moving Average: |
MA(5): 0.78 MA(20): 1.5
MA(100): 2.01 MA(250): 1.83 |
| MACD: |
MACD(12,26): -0.4 Signal(9): -0.3 |
| Stochastic oscillator: |
%K(14,3): 7.6 %D(3): 8.8 |
| RSI: |
RSI(14): 21.4 |
| 52-week: |
High: 4.55 Low: 0.65 |
| Average Vol(K): |
3-Month: 481 (K) 10-Days: 1,069 (K) |
|
Price, moving averages and Bollinger Bands |
|
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ ACER ] has closed above bottom band by 19.1%. Bollinger Bands are 79% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 4 days. This is a sign that the current trend might continue. |
|
|
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
0.8 - 0.8 |
0.8 - 0.81 |
|
Low:
|
0.73 - 0.74 |
0.74 - 0.74 |
|
Close:
|
0.74 - 0.75 |
0.75 - 0.76 |
|
Company Description |
|
Acer Therapeutics Inc., a pharmaceutical company, focuses on the acquisition, development, and commercialization of therapies for serious rare and life-threatening diseases. Its pipeline includes four clinical-stage candidates comprising EDSIVO for the treatment of vascular Ehlers-Danlos Syndrome in patients with a confirmed type III collagen mutation; ACER-001, a formulation of sodium phenylbutyrate for the treatment of various inborn errors of metabolism, including urea cycle disorders and maple syrup urine disease; ACER-801 (osanetant) for the treatment of induced Vasomotor Symptoms; and ACER-2820 (emetine), a host-directed therapy against a variety of infectious diseases, including COVID-19. The company has a research collaboration agreement with the National Center for Advancing Translational Sciences (NCATS) to develop emetine hydrochloride as a potential treatment for patients with COVID-19; and a license agreement with Sanofi to acquire worldwide rights to osanetant, a clinical-stage, selective, and non-peptide tachykinin NK3 receptor antagonist. Acer Therapeutics Inc. was incorporated in 1991 and is headquartered in Newton, Massachusetts. |
Headline News |
Wed, 22 Mar 2023
ACER THERAPEUTICS INC. : Entry into a Material Definitive Agreement, Unregistered Sale of Equity Securities, Other Events, Financial Statements and Exhibits (form 8-K) - Marketscreener.com
Wed, 22 Mar 2023
Acer Therapeutics Announces Data Presented at Society for ... - GlobeNewswire
Mon, 20 Mar 2023
Healthcare Stocks Moving Up and Down Monday: LFCR, ACER, INM, GOSS, AZYO, CODX, OMGA, SOPH - InvestorsObserver
Mon, 20 Mar 2023
Why Bed Bath & Beyond Shares Are Trading Lower By Around 24 ... - Benzinga
Fri, 17 Mar 2023
Why Baidu Shares Are Trading Higher By More Than 6%? Here Are ... - Benzinga
Fri, 17 Mar 2023
Crude Oil Down 2%; Enzo Biochem Shares Spike Higher - Acer ... - Benzinga
|
Financial Analysis |
| Price to Book Value: |
Underperform |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
| Price to Earnings: |
Underperform |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
| Discounted cash flow: |
Outperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
| Return on Assets: |
Underperform |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
| Return on Equity: |
Outperform |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
| Debt to Equity: |
Underperform |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ |
| Sector: Healthcare |
| Industry: Biotechnology |
| Shares Out. |
0 (M) |
| Shares Float |
21 (M) |
|
% Held by Insiders
|
1.069e+007 (%) |
|
% Held by Institutions
|
18.3 (%) |
|
Shares Short
|
498 (K) |
|
Shares Short P.Month
|
0 (K) |
Stock Financials |
|
EPS
|
-2.37e+007 |
|
EPS Est Next Qtl
|
0 |
|
EPS Est This Year
|
-4.87 |
|
EPS Est Next Year
|
0 |
|
Book Value (p.s.)
|
0 |
|
Profit Margin (%)
|
0 |
|
Operating Margin (%)
|
-6 |
|
Return on Assets (ttm)
|
603 |
|
Return on Equity (ttm)
|
-62.1 |
|
Qtrly Rev. Growth
|
360000 |
|
Gross Profit (p.s.)
|
0 |
|
Sales Per Share
|
0 |
|
EBITDA (p.s.)
|
1.93846e+006 |
|
Qtrly Earnings Growth
|
-0.6 |
|
Operating Cash Flow
|
0 (M) |
|
Levered Free Cash Flow
|
-23 (M) |
Stock Valuations |
|
PE Ratio
|
-0.01 |
|
PEG Ratio
|
0 |
|
Price to Book value
|
0 |
|
Price to Sales
|
0 |
|
Price to Cash Flow
|
-0.65 |
Stock Dividends |
|
Dividend
|
0 |
|
Forward Dividend
|
295590 |
|
Dividend Yield
|
0% |
|
Dividend Pay Date
|
2017-09-20 |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
Your Ad Here
|
|
